Welcome to our dedicated page for ZOETIS news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on ZOETIS stock.
Zoetis Inc. (symbol: ZTS) is a leading American pharmaceutical company and the world's largest producer of medicines and vaccinations for pets and livestock. Originally a subsidiary of Pfizer, Zoetis became an independent company following Pfizer’s spinoff of its 83% interest. Zoetis specializes in a wide range of products including anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.
The company's revenue is split between production animals (cattle, pigs, poultry, etc.), which contribute approximately 35%, and companion animals (dogs, horses, cats), which account for nearly 65%. In the U.S., Zoetis' business is predominantly focused on companion animals, while its international operations have a slight inclination towards production animals. As an industry leader, Zoetis holds the largest market share and continues to lead in innovation and product development for animal health.
Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity. Financially, Zoetis remains robust with consistent revenue growth and strategic partnerships to expand its market reach. Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.
Stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. to make informed investment decisions.
Zoetis reported its financial results for Q4 and the full year of 2022, achieving a revenue of $2.0 billion for Q4, up 4% year-over-year. The company’s net income for Q4 was $461 million, equating to $0.99 per diluted share. For the full year, Zoetis posted revenues of $8.1 billion, also reflecting a 4% increase, with net income reaching $2.1 billion or $4.49 per diluted share. Looking ahead, Zoetis expects 2023 revenue between $8.575 billion and $8.725 billion, with an operational growth forecast of 6% to 8%. Key growth drivers included companion animal products, although livestock product sales faced challenges from competition and supply issues.
The Board of Directors of Zoetis (NYSE:ZTS) has declared a dividend of $0.375 per share for Q2 2023. This dividend will be distributed on June 1, 2023, to shareholders on record as of April 21, 2023. Zoetis is a leading animal health company, generating $7.8 billion in revenue in 2021. With over 70 years of experience, they provide innovative solutions for animal care globally.
For more information on their products and services, visit www.zoetis.com.
Zoetis Inc (NYSE:ZTS) will hold a webcast and conference call on February 14, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full year 2022 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present and answer questions from analysts. Investors can access the live webcast via the Zoetis website and a replay will be available following the event. Zoetis, a leading global animal health company, reported $7.8 billion in revenue for 2021 and continues to innovate in animal care across over 100 countries.
Zoetis (NYSE: ZTS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. CEO Kristin Peck is scheduled to present at 1:30 p.m. PT and answer analyst questions. Investors can access a live audio webcast of the presentation through the company's investor relations site. A replay will also be available post-event. Zoetis, a leading animal health company, generated $7.8 billion in revenue in 2021 and operates in over 100 countries, focusing on animal care and health innovations.
The Board of Directors of Zoetis has announced a dividend of $0.375 per share for Q1 2023, marking a 15% increase from 2022. This dividend will be paid on March 1, 2023, to shareholders on record as of January 20, 2023. Executive VP and CFO Wetteny Joseph highlighted the company's robust product portfolio and global presence as key factors for generating increased cash flow for future investments and returning capital to shareholders.
Zoetis (NYSE:ZTS) will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022. Glenn David, Executive Vice President and Group President of U.S. Operations, will present at 3:30 p.m. ET. Investors can access a live audio webcast of the presentation at investor.zoetis.com/events-presentations. A replay will be available post-event. As a leading animal health company, Zoetis aims to improve animal care globally, generating $7.8 billion in revenue in 2021.
Zoetis Inc. (NYSE:ZTS) has announced a public offering of $1.35 billion in senior notes, which includes $600 million of 5.400% notes due in 2025 and $750 million of 5.600% notes due in 2032. The proceeds will be used to repay existing 3.250% senior notes due in 2023. The offering is anticipated to close on November 16, 2022, subject to standard conditions. Barclays Capital, BofA Securities, Citigroup, J.P. Morgan, and MUFG are the joint book-running managers for the offering. The securities are registered under the Securities Act of 1933.
Zoetis reported Q3 2022 revenue of $2.0 billion, a 1% increase year-over-year, with net income at $529 million or $1.13 per diluted share, reflecting decreases of 4% and 3%, respectively. Operational growth was strong, with a 5% revenue rise and 2% adjusted net income increase. The company has lowered its full-year revenue guidance to $8.000 - $8.075 billion due to supply constraints and foreign exchange impacts. Key product sales in the companion animal segment showed promise, though livestock product sales faced challenges.
Vyond has announced its Fall Release of Vyond Studio, enhancing enterprise video creation through AI integration. The new features enable businesses to produce videos up to 10X faster and 130% more engaging than traditional methods. Users can now import SVG files, utilize advanced charts, and access AI-powered tools such as Instant Video Translation into 71 languages. These updates aim to improve communication in HR, Sales, and Marketing, empowering companies like Zoetis to streamline onboarding and training initiatives.
Zoetis Inc. (NYSE:ZTS) has declared a $0.325 per share dividend for Q4 2022, payable on December 1, 2022, to shareholders on record as of November 1, 2022. With a revenue of $7.8 billion in 2021, Zoetis is a leader in animal health, driven by innovation in animal care over 70 years. Their portfolio includes medicines, vaccines, and diagnostics for animals worldwide. This dividend reflects the company's commitment to providing returns to investors while sustaining growth.
FAQ
What is the current stock price of ZOETIS (ZTS)?
What is the market cap of ZOETIS (ZTS)?
What does Zoetis Inc. specialize in?
Is Zoetis Inc. still part of Pfizer?
What percentage of Zoetis' revenue comes from companion animals?
Which segment contributes more to Zoetis' U.S. business?
How does Zoetis' international business differ from its U.S. business?
What recent achievements has Zoetis Inc. accomplished?
What are Zoetis' current projects?
What is Zoetis' market position in the industry?
Does Zoetis have any strategic partnerships?
Where can I find the latest updates on Zoetis Inc.?
